TELA Bio (TELA) Gains from Investment Securities (2018 - 2019)
TELA Bio (TELA) posted Gains from Investment Securities of $1000.0 for Q4 2019, up 102.94% on a QoQ basis from -$34000.0 in Q3 2019, and down 99.9% year-over-year from $956000.0 in Q4 2018.
Powered by 
Analysis
TELA Bio (TELA) Gains from Investment Securities (2018 - 2019) Analysis & Trends
TELA Bio has reported Gains from Investment Securities for 2 years, with the latest figure at $1000.0 in Q4 2019.
- On a quarterly basis, Gains from Investment Securities fell 99.9% year-over-year to $1000.0 in Q4 2019; TTM through Dec 2022 was -$33000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $888000.0, changed 0.11% from the prior year.
- Gains from Investment Securities was $1000.0 for Q4 2019 at TELA Bio, up from -$34000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $956000.0 in Q4 2018, with the low at -$36000.0 in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.74 Bn | 175.14 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.72 Bn | 122.50 Bn | 1.96 Bn |
| 3 | Medtronic | 116.88 Bn | 108.06 Bn | 6.34 Bn |
| 4 | Stryker | 104.10 Bn | 100.62 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.74 Bn | 63.20 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.85 Bn | 45.60 Bn | 1.35 Bn |
| 7 | Alcon | 33.03 Bn | 31.58 Bn | 1.68 Bn |
| 8 | Dexcom | 32.15 Bn | 30.20 Bn | 830.00 Mn |
| 9 | Steris | 20.63 Bn | 20.15 Bn | 684.20 Mn |
| 10 | TELA Bio | 48.87 Mn | 18.44 Mn | 13.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 1,000.00 |
| Sep 30, 2019 | -34,000.00 |
| Jun 30, 2019 | 74,000.00 |
| Mar 31, 2019 | -36,000.00 |
| Dec 31, 2018 | 956,000.00 |
| Sep 30, 2018 | -17,000.00 |